REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Proposed cancellation of trading on AIM

MaxCyteAnnouncement

15/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250415:nRSO9923Ea&default-theme=true

RNS Number : 9923E  MaxCyte, Inc.  15 April 2025

 

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED FOR THE PURPOSES OF
ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF
DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL)
ACT 2018 (ÒUK MARÓ). UPON PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION
IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

MaxCyte Inc.

(ÒMaxCyteÓ or the ÒCompanyÓ)

 

MaxCyte Announces Proposed Cancellation of Admission of its Common Stock to
Trading on AIM and Continued Listing of its Common Stock on Nasdaq

 

Approval of AIM Delisting to be Proposed at Annual Meeting of Stockholders

 

ROCKVILLE, MD, LONDON, UK, 15 April 2025 Ñ MaxCyte, Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics, today announced the CompanyÕs intention to
cancel the admission of its common stock in the Company (ÒCommon StockÓ) to
trading on the AIM market of the London Stock Exchange (ÒAIM,Ó and such
proposed cancellation, the ÒAIM DelistingÓ), subject to stockholder
approval, expected to take effect from Thursday 26 June 2025. If the AIM
Delisting is approved by stockholders, the CompanyÕs last day of trading on
AIM is expected to be Wednesday 25 June 2025.

 

The Board of Directors of the Company (the ÒBoardÓ) notes that the vast
majority of trading in the Common Stock now occurs through Nasdaq and believes
that the AIM Delisting has the potential to enhance the liquidity of trading
in the Common Stock on Nasdaq and reduce duplicative costs which arise from
retaining two listings.

 

The Company will retain its U.S. listing on the Nasdaq Global Select Market
(ÒNasdaqÓ) of Common Stock under ticker symbol MXCT.

 

Key messages:

á    Following the AIM Delisting being approved by stockholders, the
Common Stock will remain listed on Nasdaq and will only be tradeable on
Nasdaq.

á    By reference to the volume of the underlying Common Stock, more than
94 per cent. of the average daily volume of trading in the past twelve months
has taken place on Nasdaq.

á    The Board believes that the AIM Delisting could enhance the liquidity
of trading in the Common Stock on Nasdaq, as all trading will be concentrated
on a single trading venue.

á    Pursuant to the CompanyÕs certificate of incorporation, the prior
consent of stockholders of 75 per cent. of the voting power of all of the then
outstanding shares of capital stock given at a meeting of the stockholders is
necessary for the cancellation of the Common Stock from trading on AIM. A
resolution to approve the AIM Delisting in accordance with the CompanyÕs
certificate of incorporation will be proposed to the CompanyÕs annual meeting
of stockholders, which is expected to take place on Wednesday 18 June 2025.

á    A shareholder vote is not required pursuant to Rule 41 of the AIM
Rules for Companies.

á    Following the AIM Delisting, the Company will continue to engage with
UK based Shareholders.

 

The Company will seek stockholder approval for the AIM Delisting at its annual
meeting of stockholders which is expected to be held at 11.00 a.m. Eastern
Time (4.00 p.m. UK time) on Wednesday 18 June 2025 at 9713 Key West Avenue,
Suite 400, Rockville, Maryland, 20850 (the ÒAnnual MeetingÓ). The Company
intends to file a preliminary proxy statement with the U.S. Securities and
Exchange Commission (the ÒSECÓ) in relation to seeking stockholder approval
for the AIM Delisting and other matters to be voted on at the annual meeting
later today and intends to mail a definitive proxy statement to holders of its
Common Stock on the record date specified in the definitive proxy statement,
soliciting their proxy to vote at the Annual Meeting in due course.

 

A further announcement will be made upon the definitive proxy statement being
published and made available on MaxCyteÕs website at
https://investors.maxcyte.com. Any changes to the anticipated timetable of key
events set out in this announcement will also be announced. In connection with
Admission and pursuant to Rule 41 of the AIM Rules for Companies, the Company
hereby gives notice of the intended cancellation of trading of its ordinary
shares on AIM.

 

Background to the AIM Delisting

 

The Company was founded in 1998 with its headquarters and operations in
Maryland, U.S. The Common Stock was admitted to trading on AIM in March 2016
(the ÒAIM AdmissionÓ). The Company raised £10 million at the time of AIM
Admission which allowed the Company to accelerate development of its R&D
platform, expand the reach of the CompanyÕs cell therapy business to Europe
and other global markets and to extend the CompanyÕs direct sales teams and
network of distributors. The Company raised further funds in 2017, 2019, 2020
and 2021 to support its continued growth and focus on expansion of the
CompanyÕs manufacturing capabilities, technology roll out and business
development. The latter fundraises expanded the CompanyÕs stockholder base to
include a number of U.S. and specialist investors.

 

Expansion of the CompanyÕs operations and technology and expertise in cell
engineering, together with an increasing number of strategic platform licences
and associated program-related revenue, culminated in the Company conducting a
U.S. public offering in July 2021 raising gross proceeds of $202 million,
alongside a dual-listing of the Common Stock on Nasdaq. The principal purposes
of the U.S. public offering and Nasdaq listing were to obtain additional
capital to increase the CompanyÕs financial flexibility, support the
CompanyÕs operations and growth and create a public market for the Common
Stock in the U.S. enabling further access public equity markets.

 

The Company has maintained its AIM Admission for over nine years; however,
following the Nasdaq listing almost four years ago, trading of the Common
Stock on AIM has decreased to a level (in comparison to trading of the Common
Stock on Nasdaq) that the Board believes no longer justifies maintaining a
dual listing on AIM.  As at 11 April 2025, being the last practicable date
prior to the date of this announcement, approximately 20 per cent. of the
Common Stock was represented by CREST Depository Interests (ÒCDIsÓ) which
are used for settling trades on AIM in the CREST system. Furthermore, more
than 94 per cent. of the average daily trading in the Common Stock over the
past twelve months has taken place on Nasdaq.

 

Reasons for the AIM Delisting

 

The Board is seeking to implement the proposed AIM Delisting for the following
reasons:

 

á    An increasingly smaller proportion of trading in the Common Stock is
conducted on AIM via the CDIs, compared to Nasdaq and a continuation of the
decline in this proportion would likely lead to a decrease in the liquidity of
the Common Stock trading on AIM.

 

á    The AIM Delisting is expected to further enhance the liquidity of
trading in the Common Stock on Nasdaq by combining the volume of transactions
from both Nasdaq and AIM.

 

á    The cost of maintaining its AIM listing and complying with the AIM
Rules for Companies is duplicative of that for complying with the ongoing
Nasdaq listing requirements, as well as other U.S. requirements.

 

á    Time spent by internal financial and legal staff on compliance with
the AIM Rules for Companies is duplicative of that required for compliance
with the Nasdaq listing rules.

 

á    The Common Stock will continue to be listed on Nasdaq with no
interruption in trading activity.

 

á    The Directors believe that the Company has successfully achieved its
objectives of the AIM Admission, having raised significant growth capital,
expanded the CompanyÕs cell therapy business to Europe and enhanced the
CompanyÕs profile and product awareness amongst current and prospective
customers, partners and suppliers, as stated in the CompanyÕs AIM admission
document published in March 2016.

 

á    The AIM Admission has proved to be an important and effective
stepping stone in the CompanyÕs development and growth. However, given the
volume of trading occurring on Nasdaq, the Board believes that the future
benefits of its AIM Admission are limited. However, following the AIM
Delisting the Company will continue to engage with UK based Shareholders.

 

Accordingly, the Board believes that it is no longer in the best interests of
the Company, or its stockholders as a whole, for the Company to retain
admission of the Common Stock to trading on AIM.

 

Background to the Stockholder Vote

 

The requirement to seek stockholder approval for the AIM Delisting was
included in the CompanyÕs certificate of incorporation at the time of its AIM
Admission. The certificate of incorporation provides that the AIM Delisting
requires the consent of 75 per cent. of the voting power of all of the then
outstanding shares of capital stock given at a meeting of stockholders.

 

A shareholder vote is not required pursuant to Rule 41 of the AIM Rules for
Companies.

 

Details of the Annual Meeting

 

The Company plans to seek stockholder approval for the AIM Delisting at the
Annual Meeting, which is expected to be held at 11.00 a.m. Eastern Time (4.00
p.m. UK time) on Wednesday 18 June 2025 at 9713 Key West Avenue, Suite 400,
Rockville, Maryland, 20850. Details of how stockholders may attend the meeting
remotely will be included in the proxy documents. The Company intends to file
a preliminary proxy statement with the SEC later today and then, once
finalised, to mail the definitive proxy statement to holders of its shares of
Common Stock as of the record date soliciting their proxy to vote at the
Annual Meeting in due course. Copies of the preliminary and definitive proxy
statements will be publicly available in the SECÕs EDGAR filing database on
the SECÕs website at www.sec.gov
(https://protect.checkpoint.com/v2/___http:/www.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo1ZTViNDFkOTgxMmFkMzY5ZGViMDI5OTAyZDY4YzVmNDo2OmJhMmU6ZjBjOGE5Zjc4YWM3ZGI3ZmU0YWI2ZjJlNzVhYmIwZThjOWQ4MjNmZTRlODlmYWIxZjI0ZmU3ZjRiNzZiNjYwZTpwOlQ6Rg)
.

 

Effect of the AIM Delisting

 

If the AIM Delisting is approved at the Annual Meeting, stockholders will no
longer be able to buy and sell the Common Stock on AIM after a date that is
expected to be on or around Wednesday 25 June 2025. Holders of the Common
Stock who hold securities in the CREST system in the form of CDIs should read
ÒInformation for Holders of CREST Depository InterestsÓ below which explains
in more detail.

 

Following the AIM Delisting taking effect, the Company will no longer be
subject to the AIM Rules for Companies or be required to retain the services
of a nominated adviser. The Company will also no longer be subject to the QCA
Corporate Governance Code or be required to comply with the continuing
obligations set out in the Disclosure Guidance and Transparency Rules of the
Financial Conduct Authority or, provided the CompanyÕs securities remain
outside of the scope of the regulation, UK MAR. In addition, the Company and
its stockholders will no longer be subject to the provisions of the AIM Rules
for Companies relating to the disclosure of changes in significant
shareholdings in the Company, and the provisions in the CompanyÕs certificate
of incorporation related to trading on AIM will cease to have any legal effect
even though such provisions will remain in the certificate of incorporation.

 

The Company will continue to comply with all regulatory requirements for the
Nasdaq listing of the Common Stock, including all applicable rules and
regulations of the SEC and other US requirements.

 

Stockholders will continue to be notified in writing of the availability of
key documents on the CompanyÕs website, including publication of documents
filed with the SEC, as well as annual meeting documentation.

 

The Company will remain incorporated under the laws of the State of Delaware
in the U.S. The rights of stockholders will remain governed by Delaware law
and by the CompanyÕs certificate of incorporation and bylaws.

 

As a Delaware company, the Company has never been subject to the provisions of
the City Code on Takeovers and Mergers.

 

Following this announcement, and prior to the effective date of the AIM
Delisting, holders of the Common Stock may choose to sell or otherwise dispose
of their Common Stock. Any such sales of the Common Stock, if significant,
could have a negative effect on the value of the Common Stock as well as the
trading price of the Common Stock on AIM and Nasdaq, which could inhibit other
stockholdersÕ ability to sell or dispose of their Common Stock at current
trading prices.

 

Information for Holders of CREST Depository Interests

 

Subject to confirmation of the final AIM Delisting timetable and stockholder
approval, the Common Stock will continue to be traded on AIM until market
close (4.30 p.m. UK time) on a date expected to be on or about Wednesday 25
June 2025. Thereafter, subject to the AIM Delisting proceeding, there will be
no public market in the United Kingdom on which the Common Stock can be
traded, and the Common Stock will only be tradeable on Nasdaq.

 

Since the CompanyÕs listing on Nasdaq in 2021, holders in CREST in the UK
have held via CDIs, which represent the Common Stock held by CREST
International Nominees Limited (the ÒCREST NomineeÓ), as custodian in the
Depository Trust Company (ÒDTCÓ) clearance system for CREST Depository
Limited, a subsidiary of Euroclear UK & International Limited (the ÒCREST
DepositoryÓ), which is the depositary and issuer of the CDIs.

 

A CDI is a security constituted under English law issued by the CREST
Depository that represents an entitlement to international securities, in this
case the Common Stock. A CDI is issued by the CREST Depository to CREST
members and represents an entitlement to identifiable underlying securities.
Each CDI represents a share of Common Stock held by the CREST Nominee as
custodian in the DTC clearance system for the CREST Depository as the
depositary and issuer of the CDIs. The CREST DepositoryÕs relationship with
CDI-holding CREST members is governed by the CREST Deed Poll and CREST
International Manual.

 

Holders of CDIs in CREST will have the following options:

 

á    They may choose to continue to hold through CDIs in CREST, however
there will be no UK trading venue for the Common Stock. Holding by way of a
CDI will entail international custody costs and certain differences in the
nature, range and cost of corporate services, including with respect to the
manner in which voting rights can be exercised in person or by proxy, relative
to a direct holding of the Common Stock. CREST members who anticipate
continuing to hold their investment in the Common Stock in CREST via CDIs
should familiarise themselves with the CDI service offering, details of which
are included in the CREST International Manual and the terms of the CREST Deed
Poll. The CDIs will remain outstanding until the holder elects to cancel them.

 

á    They may choose to cancel the CDIs and hold via DTC, which will
require the holder to engage a US brokerage firm that is a DTC participant.
The holder will need to request the cancellation of the CDIs and the release
of the underlying Common Stock from the DTC participant account of the CREST
Nominee to the DTC account of their U.S. broker in accordance with
EuroclearÕs standard protocols.

 

á    They may choose to cancel the CDIs and hold in registered form
directly on the CompanyÕs share register, this will be in the Direct
Registration System (ÒDRSÓ) maintained by the CompanyÕs transfer agent,
Computershare Trust Company, N.A., in the United States.

 

Certain UK Tax Considerations

 

The Company cannot and does not provide any form of taxation advice to
stockholders and therefore stockholders are strongly advised to seek their own
taxation advice to confirm the consequences of (1) converting their CDIs to
Common Stock (whether before or after the AIM Delisting, and whether via DTC
or in registered form in the DRS), or (2) continuing to hold CDIs following
the AIM Delisting.

 

The following summary does not constitute legal or tax advice and is not
exhaustive. The CompanyÕs understanding of the current position for UK
individuals who are subject to taxation in the UK for relevant tax purposes is
as follows but it should be noted that the position on certain points is not
free from uncertainty and that the Company has not taken steps to confirm the
current position with His MajestyÕs Revenue & Customs. Therefore, the
following should not be relied upon by stockholders without taking further
advice (and the Company accepts no liability in respect of any such reliance
on any information provided herein on taxation matters):

 

á    It is expected that neither the AIM Delisting itself nor the
conversion by stockholders of their CDIs to Common Stock (either before or
after the AIM Delisting, and whether via DTC or in registered form in the DRS)
should be treated as a disposal for UK capital gains tax purposes.

 

á    No charge to UK stamp duty reserve tax (ÒSDRTÓ) or UK stamp duty,
should arise on the conversion of CDIs to Common Stock through the paperless
transfer of such Common Stock between DTC participant accounts, or its
registration in the DRS.  This should be the case irrespective of whether
such conversion occurs before or after the AIM Delisting.

 

á    Paperless transfers of the Common Stock through DTCÕs facilities,
and transfers of the Common Stock registered in the DRS, should continue not
to be subject to UK stamp duty or SDRT. Paperless transfers of CDIs should
continue not to be subject to UK stamp duty or SDRT provided (as is expected
to be the case) certain relevant conditions continue to be met following the
AIM Delisting. Following the AIM delisting, a document transferring title to
the Common Stock (including the Common Stock registered in the DRS) or to CDIs
may strictly be within the scope of UK stamp duty, but in practice no such
stamp duty should normally need to be paid unless the document is executed in
the UK or relates to any matter or thing to be done in the UK, and is required
to be relied on as evidence in a UK court or to be used for other official
purposes.

 

Frequently Asked Questions

 

The Company has published a set of ÒFrequently Asked QuestionsÓ on its
website at https://investors.maxcyte.com
(https://protect.checkpoint.com/v2/___https:/investors.maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo1ZTViNDFkOTgxMmFkMzY5ZGViMDI5OTAyZDY4YzVmNDo2OmIyOTM6Mjc1ZGY1MTIxNDcwZDNiNWMwOGI1ODJkNzBiYjAxYTZlNDg2ZWI2YzMwOWMzNzM2ZTk0N2QxMzhmZWZkYThiNjpwOlQ6Rg)
.

 

Additional Information and Where to Find It

The proposed AIM Delisting will be submitted to the CompanyÕs stockholders
for their consideration. The Company intends to file with the SEC a
preliminary proxy statement later today and, once finalized, a definitive
proxy statement that will be sent to all holders of record of the Common Stock
on the record date in connection with the AIM Delisting and the other matters
to be voted on at the Annual Meeting. This announcement does not contain all
the information that should be considered concerning the AIM Delisting and is
not intended to form the basis of any investment decision or any other
decision in respect of the AIM Delisting.

 

The CompanyÕs stockholders and other interested persons are advised to read,
when available, the preliminary proxy statement and the definitive proxy
statement and other documents filed in connection with the AIM Delisting, as
these materials will contain important information about the Company and the
AIM Delisting. When available, the definitive proxy statement and other
relevant materials for the proposed AIM Delisting will be provided to
stockholders of the Company as of a record date to be established for voting
on the AIM Delisting. The CompanyÕs stockholders will also be able to obtain
copies of the preliminary proxy statement, the definitive proxy statement and
other documents filed with the SEC, without charge, once available, at the
SECÕs website at www.sec.gov, or by directing a request to the Company at
MaxCyte, Inc., Attention: Investor Relations, 9713 Key West Avenue, Suite 400,
Rockville, Maryland 20850.

 

Appointment of Proxy Solicitor and Participants in Solicitation

 

The Company has engaged D.F. King & Co., Inc. (ÒD.F. KingÓ) to assist
the Company with the solicitation of proxies in connection with the annual
meeting of stockholders.

 

The Company and its directors and executive officers may be deemed
participants in the solicitation of proxies from the CompanyÕs stockholders
with respect to the proposed AIM Delisting. A list of the names of those
directors and executive officers and a description of their interests in the
Company will be contained in the CompanyÕs definitive proxy statement. To the
extent such holdings of the CompanyÕs securities may have changed since that
time, such changes have been or will be reflected on Statements of Change in
Ownership on Form 4 filed with the SEC. Additional information regarding the
interests of such participants will be contained in the definitive proxy
statement for the proposed AIM Delisting when available.

 

Anticipated Timetable of Key Events

 

 Announcement of the AIM Delisting                                7.00 a.m. (UK time) on 15 April 2025
 Filing of the preliminary Proxy Statement with the SEC           After market close US time on 15 April 2025

 Voting record date                                               22 April 2025
 Filing of the definitive Proxy Statement with the SEC            25 April 2025

 Dispatch of the final Proxy Statement to stockholders            25 April 2025
 Deadline for proxy votes for the Annual Meeting                  17 June 2025
 Annual Meeting                                                   18 June 2025
 Announcement of results of Annual Meeting                         19 June 2025
 Last day of dealings in the Common Stock on AIM                  25 June 2025
 Cancellation of admission to trading on AIM of the Common Stock  7.00 a.m. (UK time) on 26 June 2025

 

Forward-Looking Statements

 

This announcement contains Òforward-looking statementsÓ within the meaning
of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended, including in respect
of the implications of the AIM Delisting on the trading of the CompanyÕs
Common Stock and the CompanyÕs cost base and the anticipated timeline of key
events related to the proposed AIM Delisting. All statements other than
statements of historical fact contained in this announcement are
forward-looking statements. Forward-looking statements usually relate to
future events. Forward-looking statements are often identified by the words
Òbelieve,Ó Òexpect,Ó Òanticipate,Ó Òplan,Ó Òintend,Ó Òforesee,Ó
Òshould,Ó Òwould,Ó Òcould,Ó Òmay,Ó and similar expressions, including
the negative thereof. The absence of these words, however, does not mean that
the statements are not forward-looking. These forward-looking statements are
based on the CompanyÕs current expectations, beliefs and assumptions
concerning future developments and their potential effect on the Company.
While management believes that these forward-looking statements are reasonable
as and when made, there can be no assurance that future developments affecting
the Company will be those that it anticipates.

 

All of the CompanyÕs forward-looking statements involve known and unknown
risks and uncertainties, some of which are significant or beyond its control
and involve assumptions that could cause actual results to differ materially
from the CompanyÕs historical experience and its present expectations. These
forward-looking statements are subject to risks and uncertainties, including,
among other things, risks that the stockholder vote for the AIM Delisting may
not be obtained and that the anticipated trading volume in the CompanyÕs
equity securities on Nasdaq may not materialise, as well as those risks and
uncertainties described in the CompanyÕs latest Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and other documents filed from time to time by
the Company with the SEC. The Company wishes to caution investors not to place
undue reliance on any forward-looking statements, which speak only as of the
date hereof. The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise, except to the extent required by law.

 

Additional Information

 

The person responsible for arranging the release of this information on behalf
of the Company is David Sandoval, General Counsel.

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patientsÕ lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond todayÕs processes to innovate
tomorrowÕs solutions. Our ExPERTª platform, which is based on our Flow
Electroporation¨ technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATxª, STxª, GTxª and VLx ª; a
portfolio of proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide intellectual property
portfolio. By providing our partners with the right technology platform, as
well as scientific, technical and regulatory support, we aim to guide them on
their journey to transform human health. Learn more at maxcyte.com
(https://www.globenewswire.com/Tracker?data=E5yuyjzkzZo4wvqKx2w8-uT1PzbeAmsDuiSRpilmnVj24TGyATVX8wpaEmrU7b9Dov_W5D8ktDwmLd21LF26DEXMeBCszGxe7fKsvsIkp3_DoUuGt8AApiPb3gW2lXTlO4ArFWM0xvWiNY7_e3HUR25N5TCwd75OJNBfmAXRPL-o5ufeZumLPJGS8Tr2GOAHk7GNKyP375YkjrRIJ2f17lL-udYRUVy0P16uZn6I4Iw6huFrGT-w0BW6cpxU-jpPsQDf3RJHcmezdhPZRJC07eTXyb_SgexR-qzvc0cnrfAzOIXar-udApuulgzMHBhUi47rXb1ch7pdCX9Gv2zJXCTFcabO5qoKQyLo40IBDSguXYejfxYuv5Fa3vaoopyicC7aKF999UYk9rA87ENLGhoUK4hwd8447XOYjEm4cyH0GXzNfVdO163HieB6tmN_I3kbcwO62VBXa9MlGKkIluWE2f2_9erIlySFfGZREomfemQaz3aVojClgMPbj48BeyLu7nRiuA7EHEJtW-xD0YYpsShj6_Eflya9IMroQp3bw5ppAxVgS85F6RBJiahHPOR7c2L0AfXU5gqm9Yz7juljVuijfKrSPgFBe7Mt0hLgAH6IizakY5MNRFWFJDHZrffKCes5YdxjzEPr6Ac_co_sVJ8vYKXdGfZ_tu5JcJLw49yteTvp12vX7FwZa1zZaqFefUZF84g1CB7Tqa3HY-Q3ba_j1r40NR8AcejjOQMevvQpC4P3klrzcN6aJkxebSKvxHhcyyuirezqRbIvnZo-AH0RmlzAbRaXzq82TGfuY-MfZHLgskERj2RhOG_lyvjXnANbtEnCmP5Ggjgy8nOwl7HlKe4DWEgKy_yi0gMoRlqEL0DfFEM2Tsb-91FJbPxBdRVdNF3EfEdod3UZhw==)
 and follow us on X
(https://www.globenewswire.com/Tracker?data=mRsj5bEOqw2SK3Xpgr3ysqDBCVhhRJpS6iq1Fqto8RymFZEXNc8JUYB0bc17B-vF_17rULM3iYY0RTk2sMOyGGEYST62XSLhhijOrCq7C-8giesGUyA8zpk2I57tRUHi4Kx77vnIEvHGEyODMG4O1NiY_CkGI2-8T6ozqlNJhWRvFYKQ4qWj-XEI_PX67yiyQY4V3mSzkV1HXZLEBIg_5MXW0TqHRuNzT4zX4hy-yQI8einNEGgGFDp9Wm5rx3dJL4LPeXR-9vIHL1b7WBVU-uCqkkKK-zHO0bgoPM11U0ZH-KAWM9M2dB9BXvXl02n_JmJpVcFuWPw3qCXRaHktBHMbPHCzq1z3CAd6LwYrsc4Hp3L1DONJSpYWFW75EPVgPFi21oiKdekjWD9dDwBn_vTVDm0SNMRL3vdjvJwz4i2iECqJbZc3PD9dSkwe1-muN1F6xBIxv0RjNYOjR8z57oUIiH06-8vFJtCfezRZlyBKViPX02tBF-WCGmZ3Jn6mz-XX0xNhRpMPnFkS3WaT70M3MIg6Gd2VKrrb2Qre20Uqfxth-t_ntIQT3h0sL1sB1ciVc9NjCsISXU4RonSPM2ZOpjB8QbR65CoO6vG4a_KaGw_vpUiTcDYOpKtdjkXdvSEnd7o1V27g6keAK-UvCYXmad6WJAU-wLRMx2jcztbjOBgYU_Z8wYLn9Wy8mPn5uC0xI3mVKCedgnatE8v3wICQtPLDZIz7h6LPJNYBNP2FBl_i7-sLItwj53BbsjFKqRPi_ohGC2DHa8pUwSuD-cFUQwjmRlh_qZqeLKaExI-F_0kVwdJE5K63U2J7PmZuoE_BAPpXypiwxzLWztEyf9p45P5c8CGk5Y_9HGt5vr_7QND40MEHClHHcWoYQa-6obDp0nUQQKN8hkxxuP-7zA==)
 and LinkedIn
(https://www.globenewswire.com/Tracker?data=-2ctx2Ny_PKWoVv3RDatHzZXsmWhXYdNOxu59Fvuv1vMeqWyezc9OAUIDjySd2Og1V2isK_TemOpb7qnTNWn4wJVoZUX8U7uJFFbiXwIov0AKsB2-auQh5xbZXpkTp-fVxGyFv8B1s4fA1iEqZoCe3oQ-AkkG_jOXrI15jUcmBU-zr2N4PGitfbkAfLDRyZDAK4caGQKbl7oKb1LZoq4Cc05MRbS5dR8YlT3qVt1eaEd-p4N2ktXcu7P7PaDuRYWCwtVa2P6FXjf3h35gsNf6AGq8nubtrc74VU-14e9fhoUgZUlvn4bUDZdnDqNq6qTU1Hk_ZWdSa8lgzxX45cUVZJ9UQgqQyB3VBxztDE3rxvtK_1YEKNXTBUdpsRtJDyg-mNRDgB6MoFO0uBQC9bFLByETlVnvYzuanMwOZHP33ePsNUK8_nGKsNbDXCva4nv-Qz704PlAG-Cj9fDflVSKsspxkFZVBgCA2qabGBJVRqDUJf2rG-IYRCjW_09lOF5IhgJx7Yp58UtGWTOV7dCLm39nzHY0t68Wxu50qupfF3QZZd-QfMFXEjNn2-aAu-00Z6O_T31f_qjXaMSOehvCzcQxSQ0cWSsN6gevB-UkVEMOwaY2A4bpMz45E-H1-Bpo5IqpJs-64_dW7M3L2QOIV2gZZX5Quh9MBhi6UC5dcIt1uy53xFdRWxv3jGNxmDKNrLWqqtT1T6R1RXwYfLh6FUI9s4QY6Q89gH-UCbC1GgswyAyzaREv3D7hHM7yl8EgZuXfK34av4WWiBirNv-8ewIVa3RbNP7-x1B6MhCBMg-2Wl_3gPHBpwnPl8vhUmThjXQ9yqKpeUKuU4C0C_VXsU21ANdsRvraKqp3ArxxkumICBRmxlxH-RQ54dt2bzTzk7JBxHRAKdc1Sv4rwgNx0FjDff1F08kKqKpRxq61wDTxwm4P080C0ks5XOf5iJl)
.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines

+1 540-629-3137

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

 

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Mark Rogers

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKQBBDBKBPQD